Management of Intracranial Pressure in Intracerebral Hemorrhage

Indications for Mannitol

The American Heart Association/American Stroke Association recommends mannitol for the reduction of intracranial pressure (ICP) in ICH patients with clinical evidence of elevated ICP, but dexamethasone and furosemide are not routinely recommended for ICP management in ICH 1, 2
Mannitol is indicated for ICH patients with clinical evidence of elevated ICP, such as neurological deterioration, pupillary abnormalities, or decerebrate posturing 2
Mannitol is used for directly measured elevated ICP (>20-25 mmHg) in monitored patients 2
The American Heart Association/American Stroke Association suggests that mannitol can be used for cerebral edema causing mass effect 1, 3

A typical dose of mannitol is 0.25 to 0.5 g/kg IV administered over 20 minutes, every 6 hours as needed 2

Mannitol creates an osmotic gradient across the blood-brain barrier, drawing water from brain tissue to the intravascular space 2
The maximum effect of mannitol occurs after 10-15 minutes and lasts for 2-4 hours 2
Mannitol modifies cerebral hemodynamics by increasing flow velocities in the affected middle cerebral artery 1

Serum osmolality should be maintained below 320 mOsm/L during mannitol administration 2

Hypertonic saline may be more effective than mannitol for treating elevated ICP 1
Mannitol is not recommended for routine or prophylactic use in all ICH patients without evidence of increased ICP 2

The American Heart Association/American Stroke Association does not recommend dexamethasone for ICP management in ICH patients, as current guidelines do not support the use of corticosteroids for reducing ICP or improving outcomes in ICH 1, 3

The American Heart Association/American Stroke Association does not specifically recommend furosemide as primary therapy for ICP management in ICH, but it may be used adjunctively in specific clinical scenarios, such as concern for fluid overload after mannitol administration or management of hyponatremia and other post-ICH medical complications 1, 3

The American Heart Association/American Stroke Association guidelines recommend administering mannitol 0.25 to 0.5 g/kg IV over 20 minutes, repeated every 6 hours as needed, with a maximum daily dose of 2 g/kg, for managing elevated intracranial pressure or signs of impending herniation in patients with intracerebral hemorrhage and midline shift 4

Hypertonic saline (3% or 23.4%) is an equally effective alternative to mannitol at equiosmolar doses (~250 mOsm) for managing elevated intracranial pressure in patients with intracerebral hemorrhage 4

Decompressive craniectomy with or without hematoma evacuation should be considered for patients with large hematomas, significant midline shift, or refractory elevated intracranial pressure despite medical management, including mannitol, as it may reduce mortality 5